Press releasePRNewswire
NeuroSense Therapeutics
NRSNW · NASDAQ
$0.0075+$0.0008 (+11.94%)TodayMarket closed ·
No price history for this range.
Latest news
- Press releasePRNewswire
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
- Press releasePRNewswire
NeuroSense Provides Update on Nasdaq Listing Compliance
- Press releasePRNewswire
NeuroSense Provides Business Update and Progress for the First Half of 2026
- Press releasePRNewswire
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
- Press releasePRNewswire
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
- Press releasePRNewswire
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
- Press releasePRNewswire
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
- Press releasePRNewswire
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
- Press releasePRNewswire
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
- Press releasePRNewswire
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
- Press releasePRNewswire
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
- Press releasePRNewswire
/C O R R E C T I O N -- NeuroSense/
- Press releasePRNewswire
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
- Press releasePRNewswire
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
- Press releasePRNewswire
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
- Press releasePRNewswire
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.